Abiopharma

(70% Positive) Dentsply Sirona Inc (XRAY) Files Form 8-K

EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

(99% Neutral) Amneal Pharmaceuticals Inc. (AMRX) Reports Q1 2026 Financial Results

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated <em>Staphylococcus aureus</em> Bacteremia

/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

XTL Biopharmaceuticals Acquires 85% of Beyond Airs Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease

Anavex Joins ACCESS-AD, Major Initiative Funded by the EU Commission, through Clinical Evaluation of Blarcamesine as Part of Precision Medicine in AD

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

(90% Positive) Armata Pharmaceuticals Inc. (ARMP) Announces Enrollment Update for initiate Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment